Indolequinone bioreductive drugs: Kinetic factors which influence selectivity for hypoxia

Anti-Cancer Drug Design

Volumn 13, Issue 6, 1998, Pages 635-653

  Everett, Steven A ^a   Naylor, Matthew A ^a   Nolan, John ^a   Patel, Kantilal B ^a   Wardman, Peter ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Hydroquinone autoxidation; Indolequinone; Kinetics; Leaving group; Semiquinone radical

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROQUINONE; INDOLEQUINONE DERIVATIVE; OXYGEN; RADICAL; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOOXIDATION; CHEMICAL STRUCTURE; CYTOTOXICITY; ELECTRON TRANSPORT; HYPOXIC CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; AZIRIDINES; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROQUINONES; INDOLEQUINONES; INDOLES; KINETICS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; OXYGEN; PULSE RADIOLYSIS; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 0031656599     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. ADAMS, G.E. & WILLSON, R.L. (1969). Pulse radiolysis studies on the oxidation of organic radicals in aqueous solution. Transactions of the Faraday Society, 65, 2981.
2. AKHTAR, M H., BEGLEITER, A , JOHNSON, D, LOWN, L.W, MACHAUGHLIN, L. & SIM, S.K. (1975). Studies relating tO antitumour antibiotics. Part VI. Correlation of covalent crosslinking of DNA by bifunctional aziridinoquinones with their antineoplastic activity. Canadian Journal of Chemistry, 53, 2891.
3. BAILEY, S.M., SUGGETT, N., WALTON, M.I. & WORKMAN, P. (1992). Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents - indoloquinones and diaziridinyl benzoquinones. International Journal of Radiation Oncology Biology Physics, 22, 649.
4. BORAUCH, R C. & SKIBO, E.B. (1994). A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems. Journal of Medicinal Chemistry, 37, 1625.
5. BUTLER, J., HOEY, B.M. & LEA, J.S. (1987). The reduction of antitumour diaziridinyl benzoquinones. Biochimica et Biophysica Acta, 925, 144.
6. BUTLER, J, SPANSWICK, V.J. & CUMMINGS, J. (1996). The autoxidation of the reduced forms of EO9. Free Radical Research, 25, 141.
7. BUXTON, G.V. & STUART, C.R. (1995). Re-evaluation of the thiocyanate dosimeter for pulse radiolysis. Journal of the Chemical Society Faraday Transactions, 91, 279.
8. CADENAS, E., MIRA, D., BRUNMARK, A , LIND, C., SEGURA-AGUILAR, J. & ERNSTER, L. (1988). The effect of superoxide dismutase on the autoxidation of various hydroquinones - a possible role for superoxide dismutase as a superoxide: semiquinone oxidoreductase. Free Radical Biology and Medicine, 5, 71.
9. CARTER, S.K. & CROOKE, S.T. (1979). Mitomycin C; Current Status and New Developments. Academic Press: New York.
10. CASNER, M.L , REMERS, W A. & BRADNER, WT. (1985). Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins. Journal of Medicinal Chemistry, 28, 921.
11. CONNORS, T. A. (1996). Bioreductive agents, hypoxic cells and therapy. European Journal of Cancer, 32A, 1833-1834.
12. COSBY, L.A., PARDINI, R.S., BIAGINI, R.E., LAMBERT, TL , LIN, A.J., HUANG, Y.M., HWANG, K M. & SARTORELLI, A.C. (1976). Mode of action of the bioreductive alkylating agent 2,3-bis(chloromethyl)-1,4-naphthoquinone. Cancer Research, 36, 4023.
13. COTTERILL, A S., MOODY, C.J , MORTIMER, R.J., NORTON, C L , O'SULLIVAN, N , STEPHENS, M.A., STRADIOTTO, N.R., SWANN, E. & STRATFORD, I.J. (1994). Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted Cyclopropamitosenes and related indolequinones. Journal of Medicinal Chemistry, 37, 3834.
14. DIRIX, L.Y., TONNESEN, F., CASSIDY, J., EPELBAUM, R., TEN BOKKEL HUININK, W.W., PAVLIDIS, N., SORIO, R , GAMUCCI, T , WOLFF, I., TE VELDE, A., LAN, J & VERWEIJ, J (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. European Journal of Cancer, 32A, 2019.
15. HODGES, J.C. & REMERS, W.A. (1981). Synthesis and antineoplastic activity of mitosene analogues of the mitomycins. Journal of Medicinal Chemistry, 24, 1184.
16. HOEY, B.M., BUTLER, J. & SWALLOW, A.J (1988). Reductive activation of Mitomycin C. Biochemistry, 27, 2608.
17. ISHII, T & FRIDOVICH, I. (1990). Dual effects of superoxide dismutase on the autoxidation of 1,4-naphthohydroquinone. Free Radical Biology and Medicine, 8, 21.
18. IYENGAR, B S., REMERS, W A & BRAUNER, W.T. (1986). Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes. Journal of Medicinal Chemistry, 29, 1864.
19. JAFFAR, M., NAYLOR, M.A., LOCKYER, S D, PHILLIPS, R M., EVERETT, S A , ADAMS, G E & STRATFORD, I J (1998a). 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione] prop-2-en-1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anti-Cancer Drug Design, 13, 105.
20. JAFFAR, M., NAYLOR, M A., ROBERTSON, N & STRATFORD, I.J. (1998b). Targeting hypoxia with a new generation of indolequinones. Anti-Cancer Drug Design, 13, 593.
21. KING, C.L , HITTELMAN, W.N. & LOO, T.L (1984). Induction of DNA strand breaks and cross-links by 2,5-diaziridinyl-3,5-bis[carboethoxyamino]-1,4-benzoquinone in Chinese hamster ovary cells. Cancer Research, 44, 5634.
22. LANDRISCINA, M., REMIDDI, F., RIA, F., PALAZZOTTI, B , DE LEO, M.E., IACOANGELI, M , ROSSELLI, R., SCERRATI, M. & GALEOTTI, T. (1996). The level of MnSOD is directly correlated with grade of brain tumours of neuroepithelial origin. British Journal of Cancer, 74, 1877.
23. LEADBETTER, G., FROST, D L , EKWURIBE, N N & REMERS, W A. (1974). Mitomycin antibiotics. Synthesis of 1-substituted 7-methoxymitosenes. Journal of Organic Chemistry, 39, 3580.
24. LI, V S., CHOI, D., WANG, Z., JIMENEZ, L.S , TANG, M. & KOHN, H (1996). The role of the C-10 substituent in mitomycin C-1 DNA bonding. Journal of the American Chemical Society, 118, 2326.
25. LIN, A J & SARTORELLI, A.C. (1973). 2,3-Bis(methylene)-1,4-benzoquinone. The active intermediate of bioreductive alkylating agents. Journal of Organic Chemistry, 38, 813.
26. LIN, A J , COSBY, L A., SHANKY, C W. & SARTORELLI, A C. (1972). Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. Journal of Medicinal Chemistry, 15, 1247.
27. LIN, T , TEICHER, B. & SARTORELLI, A. (1980). 2-Methylanthraquinone derivatives as potential bioreductive alkylating agents. Journal of Medicinal Chemistry, 23, 1237.
28. MALIEPAARD, M., DE MOL, N.J., JANSSEN, L H M., HOOGVLIET, J C , VAN DER NEUT, W , VERBOOM, W &. REINHOUDT, D.N. (1993). Reductive activation of potential antitumor mitosene compounds. Journal of Medicinal Chemistry, 36, 2091.
29. MIZUNO, N.S. & GILBOE, D.P. (1970). Binding of streptonigrin derivatives to DNA. Biochimica et Biophysica Acta, 224, 319.
30. MOODY, C.J., O'SULLIVAN, N., STRATFORD, I.J., STEPHENS, M.A , WORKMAN, P., BAILEY, S.M. & LEWIS, A. (1994). Cyclopropamitosenes: novel bioreductive anticancer agents - mechanism of action and enzymic reduction. Anti-Cancer Drugs, 5, 367.
31. NAYLOR, M.A., JAFFAR, M., NOLAN, J., STEPHENS, M.A., BUTLER, S., PATEL, K B., EVERETT, S.A., ADAMS, G.E, & STRATFORD, I J. (1997). 2-Cyclopropyl indoloquinones and their analogues as bioreductively-activated antitumor agents: structure-activity in vitro and efficacy in vivo. Journal of Medicinal Chemistry, 40, 2335.
32. NAYLOR, M.A., SWANN, E , EVERETT, S.A., JAFFAR, M., NOLAN, J., ROBERTSON, N., LOCKYER, S , PATEL, K.B., DENNIS, M.F., STRATFORD, M.R.L., WARDMAN, P., ADAMS, G.E., MOODY, C.J. & STRATFORD, I J (1998). Indolequinone anti-tumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. Journal of Medicinal Chemistry, in press.
33. OBERLEY, T.D. & OBERLEY, L W. (1997). Antioxidant enzyme levels in cancer. Histology and Histopathology, 12, 525
34. OOSTVEEN, E.A & SPECKAMP, W.N. (1987). Mitomycin analogues I. Indoloquinones as (potential) bisalkylating compounds. Tetrahedron, 43, 255.
35. ORLEMANS, E.O.M., VERBOOM, W, SCHELTINGA, M.W., REINHOUDT, D.N., LELIEVELD, P., FIEBIG, H.H., WINTERHALTER, B.R., DOUBLE, J.A. & BIBBY, M.C. (1989). Synthesis, mechanism of action, and biological evaluation of mitosenes. Journal of Medicinal Chemistry, 32, 1612.
36. PHILLIPS, R.M. (1996). Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione]prop-β-en- α-ol (EO9) by human DT-diaphorase. Biochemical Pharmacology, 52, 1711.
37. PLUMB, J A. & WORKMAN, P. (1994). Unusually marked hypoxic senitization to inoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase. International Journal of Cancer, 56, 134.
38. PLUMB, J.A. GERRITSON, M & WORKMAN, P. (1994). DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. British Journal of Cancer, 70, 1136.
39. PUNNONEN, K., AHOTUPA, M., ASAISHI, K., HYÖTY, M., KUDO, R. & PUNNONEN, R. (1994). Antioxidant enzyme activities and oxidative stress in human breast cancer. Journal of Cancer Research and Clinical Oncology, 120, 374.
40. RILEY, R.B. & WORKMAN, P. (1992). Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochemical Pharmacology, 43, 167.
41. ROCKWELL, S., SARTORELLI, A.C., TOMASZ, M. & KENNEDY, K A. (1993). Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Reviews, 12, 165.
42. RONGABO, L., BIANCHET, M.A., TALALAY, P & AMZEL, M. (1995). The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proceedings of the National Academy of Sciences, USA, 92, 8846.
43. ROSS, D., BEALL, H.D., SIEGEL, D., TRAVER, R.D. & GUSTAFSON, D.L. (1996). Enzymology of bioreductive drug activation. British Journal of Cancer, 74, S1.
44. SCHELLENS, J H.M., LOOS, W., BEIJNEN, J.H , STOTER, G. & VERWEIJ, J (1993). Sensitive isocratric high-performance liquid chromatographic determination of a novel indoloquinone cytoxic drug (EO9) in human plasma and urine. Journal of Chromatography, 615, 309.
45. + from hydrogen peroxide formation in pulse-irradiated oxygenated water. Journal of Physical Chemistry, 72, 626.
46. SPECKAMP, W.N & OOSTVEEN, E A. (1987). Indoloquinone compounds. International Patent WO87/06227.
47. TOKUNAGA, J. (1975). Solubilities of oxygen, nitrogen and carbon dioxide in aqueous alcohol solutions. Journal of Chemical and Engineering Data, 20, 41.
48. TOMASZ, M., MERCADE, C.M., OLSEN, J. & CHATTERJIE, N (1974). The mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro. Biochemistry, 13, 4878.
49. TOMASZ, M., CHOWDARY, R., LIPMAN, R., SHIMOTAKAHARA, S., VEIRO, D , WALKER, V. & VERDINE, G.L. (1986). Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of a covalent adduct. Proceedings of the National Academy of Sciences, USA, 83, 6702.
50. TOMASZ, M., LIPMAN, R , CHOWDARY, D , PAWLAK, J., VERDINE, G.L. & NAKANISHI, K. (1987). Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science, 235, 1204.
51. VAUPEL, P & HÖCKEL, M. (1998). Oxygenation of human tumours. In Blood Perfusion and Microenvironment of Tumors. Molls, M. & Vaupel, P. (eds), p. 63. Springer: New York.
52. 2 measurements. Cancer Research, 51, 3316.
53. WALTON, M.I., SUGGETT, N. & WORKMAN, P. (1992). The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. International Journal of Radiation Oncology Biology Physics, 22, 643.
54. WARDMAN, P. & CLARKE, E.D. (1987). Redox properties and rate constants in free-radical mediated damage. British Journal of Cancer, 55, 172.
55. WARDMAN, P., CANDEIAS, L.P., EVERETT, S.A., and TRACY, M. (1994). Radiation chemistry applied to drug design. International Journal of Radiation Biology, 65, 35.
56. WARDMAN, P (1989). Reduction potentials of one-electron couples involving free radicals in aqueous solution. Journal of Physical and Chemical Reference Data, 18, 1637.
57. WARDMAN, P. (1990). The reduction potential of benzyl viologen: an important reference compound for oxidant/radical couples. Free Radical Research Communications, 14, 57.
58. WARDMAN, P., DENNIS, M.F., EVERETT, S.A., PATEL, K.B., STRATFORD, M.R.L & TRACY, M. (1995). Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs. Biochemical Society Symposia, 61, 171.
59. WILSON, I., WARDMAN, P., LIN, T. & SARTORELLI, A. (1986). One-electron reduction of 2- and 6-methyl-1,4-naphthoquinone bioreductive alkylating agents. Journal of Medicinal Chemistry, 29, 1381.
60. WORKMAN, P. & WALTON, M.I. (1990). Enzyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes. Adams, G.E. (ed.), p. 173. Plenum Press: New York.
61. WORKMAN, P. (1992). Bioreductive mechanisms. International Journal of Radiation Oncology Biology Physics, 22, 631.
62. WORKMAN, P. (1994). Enzyme-directed drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncology Research, 6, 461.